Population-based colorectal cancer screening programmes using a faecal immunochemical test: Should faecal haemoglobin cut-offs differ by age and sex?

BMC Cancer

Volumn 17, Issue 1, 2017, Pages

  Arana Arri, Eunate ^a   Idigoras, Isabel ^b   Uranga, Begoña ^c   Pérez, Raquel ^d   Irurzun, Ana ^c   Gutiérrez Ibarluzea, Iñaki ^e   Fraser, Callum G ^f   Portillo, Isabel ^f   Luis Hurtado, José ^g   de No, Carmen ^g   Enciso, Carlos ^g   Escalante, Maite ^g   Atarés, Begoña ^g   Aguirre, José Javier ^g   Pereda, Esther ^g   Marañón, Edurne ^g   Otazua, Pedro ^g   Fernández, María ^g   Egido, José Francisco ^g   Zapata, Eva ^g   Zubiaurre, Leire ^g   Rodríguez, Juana Mari ^g   Sampedro, Pedro Esteban ^g   Goyeneche, Marisa ^g   Arrinda, José María ^g   Jauregui, Mari Luz ^g   Gómez, Marta ^g   Saiz, Marta ^g   Bujanda, Luis ^g   Gil, Inés ^g   Montalvo, Isabel ^g   Larzabal, José Miguel ^g   Garmendia, Maddi ^g   Izquierdo, Fernando ^g   Fernández, Francisco Javier ^g   Rodríguez, Iago ^g   Huerta, Alain ^g   de Miguel, Eduardo ^g   Barredo, Inmaculada ^g   Bao, Fidencio ^g   Hernández, Anaiansi ^g   Rodriguez, Isabel ^g   Fernández Landa, María José ^g   Imaz, María ^g   Calderón, Angel ^g   Polo, Francisco ^g   Arbide, Nagore ^g   Lantarón, Gaspar ^g   Quesada, Cristina ^g   Marzana, Itziar ^g   Ojembarrena, Enrique ^g   Cortés, Haritz ^g   Casado, Iñaki ^g   Zaballa, Manuel ^g   Ramírez, Mar ^g   Aperribay, Amaia ^g   Amezaga, Cristian ^g   Martínez Indart, Lorea ^g   Indart, Iraide ^g   Imaz Ayo, Ariane ^g   Imaz Ayo, Natale ^g   de la Cruz, María ^g   Bidaurrazaga, Joseba ^g   Muniozguren, Nerea ^g   Larrañaga, Nerea ^g   Audicana, Covadonga ^g   Bilbao, Isabel ^g   Bilbao, José Luis ^g   Millán, Eduardo ^g   Unanue, Saloa ^g   Mendizábal, Nere ^g   Saiz, Carlos ^g   Rodríguez, Santiago ^g   more..

^a BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^b The Basque Health Service   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d HOSPITAL DE CRUCES   (Spain)

^e Osteba   (Spain)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g NONE

Author keywords

Adenoma; Colorectal cancer; Faecal immunochemical test; Faecal occult blood test; Interval cancers; Screening

Indexed keywords

HEMOGLOBIN;

ADULT; AGE; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; FEMALE; HEALTH PROGRAM; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOASSAY ANALYZER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OCCULT BLOOD TEST; OCCULT BLOOD TEST KIT; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREDICTIVE VALUE; PROGRAM EFFECTIVENESS; PROSPECTIVE STUDY; REFERENCE VALUE; SEX DIFFERENCE; STANDARDIZATION; AGE DISTRIBUTION; BLOOD; COLORECTAL TUMOR; EARLY CANCER DIAGNOSIS; MASS SCREENING; METABOLISM; OCCULT BLOOD; PROCEDURES; SENSITIVITY AND SPECIFICITY; SEX FACTOR; SPAIN;

AGE DISTRIBUTION; AGED; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HEMOGLOBINS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEX FACTORS; SPAIN;

EID: 85028500818     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-017-3555-3     Document Type: Article

References (45)

1. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472-7.
2. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467-71.
3. Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004;126:1674-80.
4. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota colon cancer control study. N Engl J Med. 1993;328:1365-71.
5. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687-96.
6. International Agency for Research on Cancer (World Health Organization). EUCAN. 2015. http://eco.iarc.fr/eucan/Cancer.aspx?Cancer=10. (Accessed 25 July 2015).
7. Council Recommendation of 2 December 2003 on Cancer Screening (2003/878/EC). Official Journal of the European Union 16.02.2003. L327/34. https://ec.europa.eu/jrc/sites/default/files/2_December_2003%20cancer%20screening.pdf. (Accessed 25 July 2015).
8. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2007;56:210-4.
9. Van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood test for colorectal cancer in a screening population. Gastroenterology. 2008;135:82-90.
10. Segnan N, Patnick J, von Karsa L. European Commission. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Brussels: European Commission; 2011. p. 277.
11. Halloran SP, Launoy G, Zappa M. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition. Faecal occult blood testing. Endoscopy. 2012;44:SE65-87.
12. Ventura L, Mantellini P, Grazzini G, et al. The impact of immunochemical faecal occult blood testing on colorectal cancer incidence. Dig Liver Dis. 2014;46:82-6.
13. Giorgi Rossi P, Vicentini M, Sacchettini C, et al. Impact of screening program on incidence of colorectal cancer: a cohort study in Italy. Am J Gastroenterol. 2015;110(9):1359-66.
14. Lee JK, Liles EG, Bent S, et al. Accuracy of fecal immunochemical test for colorectal cancer. Systematic review and meta-analysis. Ann Intern Med. 2014;160:171-81.
15. García M, Milà N, Binefa G, et al. False-positive results from colorectal cancer screening in Catalonia (Spain), 2000-2010. J Med Screen. 2012;19:77-82.
16. Stegeman I, Wijkerslooth TR, Stoop EM, et al. Risk factors for false positive and for false negative test results in screening with fecal occult blood testing. Int J Cancer. 2013;133:2408-14.
17. Denters MJ, Deutekom M, Essink-Bot ML, et al. FIT false-positives in colorectal cancer screening experience psychological distress up to 6 weeks after colonoscopy. Support Care Cancer. 2013;21:2809-15.
18. Ming-Fang A, Li-Sheng S, Yueh-Hsia S, et al. A new insight into fecal haemoglobin concentration-dependent predictor for colon neoplasia. Int J Cancer. 2014;135:1203-12.
19. Steele RJC, McDonald P, Digby J, et al. Clinical outcomes using a faecal immunochemical test for haemoglobin as first-line test in a national programme constrained by colonoscopy capacity. UEG J. 2013;1:198-205.
20. Portillo I, Idigoras I, Ojembarrena E, et al. Lesiones detectadas en el programa de cribado de cáncer colorrectal en el País Vasco: primera ronda 2009-2011. Gastroenterol Hepatol. 2013;36:301-8.
21. Izarzugaza MI, Martínez R, Audícana C, Larrañaga N, Hernández E, Tobalina MC, et al. (2010). Cancer in the Basque Country. Incidence, mortality, survival and their trends. Vitoria-Gasteiz: Department of Health of the Basque Government, Servicio Central de Publicaciones del Gobierno Vasco, 126. Available at: http://www.osakidetza.euskadi.eus/contenidos/informacion/estado_salud/es_5463/adjuntos/cancer_en.pdf. (Accessed 20 Feb 2016).
22. Massat NJ, Moss SM, Halloran SP, Duffy SW. Screening and primary prevention of colorectal cancer: a review of sex-specific and site-specific differences. J Med Screen. 2013;20:125-48.
23. van Turenhout OFA, van der Hulst RWM, et al. Prospective cross-sectional study on faecal immunochemical tests: sex specific cut-off values to obtain equal sensitivity for colorectal cancer? BMC Gastroenterol. 2014;14:1-10.
24. Fraser CG, Rubeca T, Rapi S, Chen LS, Chen HH. Faecal haemoglobin concentrations vary with sex and age, but data are not transferable across geography for colorectal cancer screening. Clin Chem Lab Med. 2014;52:1211-6.
25. Alvarez-Urturi C, Andreu M, Hernandez C, Perez-Riquelme F, Carballo F, Ono A, Cruzado J, Cubiella J, Hernandez V, Mao CG, Perez E, Salas D, Andrés M, Bujanda L, Portillo I, Sarasqueta C, Quintero E, Morillas JD, Lanas A, Sostres C, Augé JM, Castells A, Bessa X; COLONPREV study investigatorsImpact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. Dig Liver Dis 2016;pii: S1590-8658(15)30040-30042.
26. Kapidzic A, van de Meulen P, Hol L, et al. Gender differences in fecal immunochemical test performance for early detection of colorectal neoplasia. Clin Gastroenterol Hepatol. 2015;13:1464-71.
27. Symonds EL, Osborne J, Cole SR, Bampton P, Fraser R, Young GP. Gender differences in faecal haemoglobin concentration. J Med Screen. 2016;23(1):54.
28. Wilschut JA, Habbema JDF, van Leerdam E, et al. Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst. 2011;103:1741-51.
29. Auge JM, Pellise M, Escudero JM, et al. Risk stratification for advanced colorectal neoplasia according to fecal haemoglobin concentration in colorectal cancer screening program. Gastroenterology. 2014;147:628-36.
30. Stegeman I, Wijkerslooth TR, Stoop EM, et al. Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut. 2014;63:466-71.
31. Steele RJ, McClements P, Watling C, et al. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut. 2012;61:576-81.
32. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cáncer. N Engl J Med. 2010;362:1795-803.
33. Ministerio de Sanidad y Consumo. The National Health System Cancer Strategy. Madrid, update 2009. Madrid, Spain: Ministerio de Sanidad y Consumo. p. 2009. http://www.msssi.gob.es/organizacion/sns/planCalidadSNS/pdf/ActualizacionEstrategiaCancer.pdf. (Accessed 25 July 2015).
34. Zubero MB, Arana-Arri E, Pijoán JI, et al. Population-based colorectal cancer screening: comparison of two fecal occult blood test. Front Pharmacol. 2014;4(175):1-8.
35. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th editiion of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-1474.
36. Symonds EL, Osborne JM, Cole SR, et al. Factors affecting faecal immunochemical test positive rates: demographic, pathological, behavioural and environmental variables. J Med Screen. 2015;22:187-93.
37. Fraser CG. Assessment of faecal haemoglobin concentration distributions in vital for faecal immunochemical test (FIT)-based colorectal cancer screening programmes. J Med Screen. 2016;23:52-3.
38. Sung JJ, Lau JY, Young GP, et al. Asia Pacific consensus recommendations for colorectal cancer screening. Gut. 2008;57:1166-76.
39. Brenner H, Hoffmeister M, Stegmaler C, et al. Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies. Gut. 2007;56:1585-9.
40. Flerlitsch M, Reinhart K, Pramhas S, et al. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA. 2011;306:1352-8.
41. Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal-cancer screening for detection of advanced adenomas. N Engl J Med. 2006;355:1863-72.
42. Digby J, Fraser CG, Carey FA, et al. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited. J Med Screen 2016;23(3):130-134.
43. Kim NH, Kwon MJ, Kim HY, et al. Fecal haemoglobin concentration is useful for risk stratification of advanced colorectal neoplasia. Dig Liver Dis. 2016;48(6):667-672.
44. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, et al. Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomark Prev. 2012;21:728-36.
45. Digby J, McDonald PJ, Strachan JA, Libby G, Steele RJ, Fraser CG. Deprivation and faecal haemoglobin: implications for bowel cancer screening. J Med Screen. 2014;21(2):95-7.